Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.
Kraehling JR, Sessa WC.
Circ Res · research-article; review; journal article · DOI 10.1161/circresaha.117.303776 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för nelociguat. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
7 hitsThe Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
Sandner P, Berger P, Zenzmaier C.
Gerontology · review; journal article · DOI 10.1159/000450946Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS.
Gnoth MJ, Hopfe PM, Czembor W.
Bioanalysis · journal article · DOI 10.4155/bio.14.257Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K.
J Sex Med · journal article · DOI 10.1111/jsm.12095Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP, Evgenov OV.
Handb Exp Pharmacol · review; journal article · DOI 10.1007/978-3-642-38664-0_12Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.
Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2012.00128Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure.
Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabé J, Alexandre L, Giuliano F.
Eur Urol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.eururo.2011.07.052